300363.SZ
博腾股份
SZSE · Healthcare · C 制造业 · CN
CNY 20.46
−6.53%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
7.4x
EV/EBITDA
22.0x
Market Cap
CNY 11.12B
MomentumView details →
1D Return
−6.53%
YTD Return
−15.36%
RSI (14)
50.3
ValuationView details →
P/E (Fwd)
7.4x
EV/EBITDA
22.0x
Market Cap
CNY 11.12B
RSI (14)
50.3
MomentumView details →
1D Return
−6.53%
YTD Return
−15.36%
Similar companies
Latest newsMore news →
Porton Pharma Solutions terminated its Slovenia overseas project, leading to large asset impairments and write-offs that reduced net profit by over 350 million yuan.13d agoPorton Pharma Solutions reported a net loss of 224 million yuan for the first half of 2026, swinging from a profit a year earlier.14d agoPorton Pharma Solutions' second-tier subsidiary Suzhou Porton Biopharmaceutical Co., Ltd. obtained a Drug Manufacturing License issued by the Jiangsu Provincial Drug Administration, valid until July 26, 2031, qualifying it to undertake commercial contract manufacturing of cell and gene therapy products.32d ago